Supplementary

Table S1 The literature search strategy and the results of searching in PubMed

Search step	Query	Results
1	((((Chronic kidney disease[MeSH Major Topic]) OR (chronic kidney disease [Title/Abstract])) OR (chronic renal failure[Title/Abstract])) OR (diabetic nephropathy[Title/Abstract])) OR (diabetic kidney disease[Title/Abstract])	149102
2	(finerenone) OR (BAY 94-8862)	87
3	(((((((Randomized controlled trial[Publication Type]) OR (controlled clinical trial[Publication Type])) OR (randomized[Title/Abstract])) OR (placebo[Title/Abstract])) OR (randomly[Title/Abstract])) OR (trial[Title/Abstract])) OR (groups[Title/Abstract])) NOT ((Animals[MeSH Terms]) NOT (humans[MeSH Terms]))	2783946
4	((((((Chronic kidney disease[MeSH Major Topic]) OR (chronic kidney disease[Title/Abstract])) OR (chronic renal failure[Title/Abstract])) OR (diabetic nephropathy[Title/Abstract])) OR (diabetic kidney disease[Title/Abstract])) AND ((finerenone) OR (BAY 94-8862))) AND (((((((Randomized controlled trial[Publication Type])) OR (controlled clinical trial[Publication Type])) OR (randomized[Title/Abstract])) OR (placebo[Title/Abstract])) OR (trial[Title/Abstract])) OR (groups[Title/Abstract])) NOT ((Animals[MeSH Terms])) NOT (humans[MeSH Terms])))	26

Generally, electronic databases including PubMed, Embase, and the Cochrane Library databases were searched from database inception to December 2020. The search items used were "chronic kidney disease", "chronic renal failure", "diabetic nephropathy", "diabetes mellitus", and "finerenone", "BAY 94–8862", "randomized controlled trial". The search was limited to human subjects, and no language restrictions were applied. A further search was conducted by manually reviewing conference proceedings and the references of review articles to identify potentially relevant studies. The search terms in PubMed for example, are as follows: (((((Chronic kidney disease[MeSH Major Topic]) OR (chronic kidney disease[Title/Abstract])) OR (chronic renal failure[Title/Abstract])) OR (diabetic nephropathy[Title/Abstract])) OR (diabetic kidney disease[Title/Abstract])) AND ((finerenone) OR (BAY 94-8862))) AND (((((Randomized controlled trial[Publication Type])) OR (controlled clinical trial[Publication Type])) OR (randomized[Title/Abstract])) OR (placebo[Title/Abstract])) OR (randomly[Title/Abstract])) OR (trial[Title/Abstract])) OR (groups[Title/Abstract])) NOT ((Animals[MeSH Terms]) NOT (humans[MeSH Terms]))).

Table S2 The time points of urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) selected for analysis

Study	Selected time points of the outcomes		
	UACR	eGFR	
Bakris et al., 2015	baseline visit and end of study visit (month 3)	baseline visit and end of study visit (month 3)	
Bakris et al., 2020	baseline visit and end of study visit (month 30)	baseline visit and end of study visit (month 30)	
Katayama et al., 2017	baseline visit and end of study visit (month 3)	baseline visit and end of study visit (month 3)	
Pitt <i>et al.</i> , 2013	baseline visit and end of study visit (month 1)	baseline visit and end of study visit (month 1)	

UACR, urinary albumin-creatinine ratio; eGFR, estimated glomerular filtration rate.




Figure S1 Risk of bias of included studies. (A) Risk of bias graph. (B) Risk of bias summary.




Figure S2 Publication bias of funnel plot for adverse events.




Figure S3 Publication bias of funnel plot for UACR.




Figure S4 Publication bias of funnel plot for eGFR.